Guy Goldberg

CEO, Redhill Biopharma

Search every verified Guy Goldberg interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Guy Goldberg, Chief Business Officer of RedHill Biopharma, has presented the company's pipeline and commercial operations at several investor conferences between 2020 and 2025. At the 18th Annual European Life Sciences CEO Forum in May 2025, Goldberg discussed the company's development of opaganib for acute radiation syndrome (ARS) in collaboration with BARDA, noting that the study is underway and has generated positive data. He also highlighted the company's commercial product Talicia for H. pylori infection, stating that updated guidelines could drive revenue growth in coming quarters, and mentioned plans for an additional study of RHB-104 for Crohn's disease using endoscopic data. In earlier appearances, Goldberg described RedHill as a fully integrated specialty biopharmaceutical company with three FDA-approved commercial products and a late-stage pipeline. He stated that the company's annualized revenues exceeded $80 million as of Q1 2021 and that it had a cash position of over $90 million at that time. Goldberg characterized opaganib as a host-directed SK2 inhibitor with a dual mechanism of action being investigated for COVID-19, ARS, and oncology, and noted that the company was pursuing regulatory pathways including potential emergency use authorization applications. He also emphasized the public health importance of H. pylori eradication, citing its classification by the WHO as a carcinogen.